Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UPA-ECx1 appears to be a code name or investigational designation for a drug regimen involving ulipristal acetate (UPA) used in the context of emergency contraception or possibly medical abortion. Ulipristal acetate is a selective progesterone receptor modulator primarily used as an emergency contraceptive pill, and it has also been studied in combination with misoprostol for early medical abortion regimens. The mechanism of action involves inhibition or delay of ovulation and alteration of endometrial receptivity, making the endometrium inhospitable to embryo implantation[1][2]. There is no evidence that "UPA-ECx1" refers to an approved product, brand, or widely recognized formulation beyond its use as a study code.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on UPA-ECx1.